Hogan Lovells advises Recordati on licensing and supply agreements with Amarin for the commercialization of Vazkepa

Hogan Lovells advises Recordati on licensing and supply agreements with Amarin for the commercialization of Vazkepa®

Press releases | 26 June 2025

Milan, London 28 June 2025 – Global law firm Hogan Lovells has advised Recordati on the licensing and supply agreements with Amarin for the commercialization of the cardiovascular drug Vazkepa® in 59 countries, focusing on Europe.

Recordati will pay Amarin US$25 million upfront, in addition to commercial milestones up to a total maximum of US$150 million. Amarin will supply the finished product to Recordati and, according to the terms of the agreements, will be entitled to receive royalties for the supply of the product.

The cross-practice and multi-jurisdictional Hogan Lovells team that advised Recordati was led and coordinated by partners Francesco Stella and Penny Powell, and included associates Bea Watts and James Furneaux, partner Ed Bowyer and associate Imtiyaz Chowdhury from the London office, partner Vittorio Moresco, senior associates Fabrizio Grillo and Marina Massaro from the Milan office, partner Luis Enrique de la Villa and associate Lucia Garcia Martinez from the Madrid office. Hogan Lovells offices in France, Ireland, the Netherlands, and the United States, as well as local law firms in Austria, Portugal, Sweden, and Switzerland, were also involved.

The Hogan Lovells team worked closely with Recordati's in-house legal team, led by Bibianne Bon, Chief Legal Officer, and particularly with Silvestro Nasturzio, Legal Counsel.